Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4+Anti-PD-1 Therapy

被引:0
|
作者
Buchbinder, Elizabeth. I. I. [1 ,2 ,3 ,7 ]
Pfaff, Kathleen. L. L. [4 ,5 ]
Turner, Madison. M. M. [4 ,5 ]
Manos, Michael [5 ]
Ouyang, Olivia [5 ]
Ott, Patrick. A. A. [1 ,2 ,3 ,5 ]
Giobbie-Hurder, Anita [6 ]
Rodig, Scott. J. J. [3 ,4 ,5 ]
Hodi, F. Stephen [1 ,2 ,3 ,5 ]
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[2] Brigham & Womens Hosp, Dept Med, Boston, MA USA
[3] Harvard Med Sch, Boston, MA USA
[4] Brigham & Womens Hosp, Dept Pathol, Boston, MA USA
[5] Dana Farber Canc Inst, Ctr Immuno Oncol, Boston, MA USA
[6] Dana Farber Canc Inst, Dept Data Sci, Div Biostat, Boston, MA USA
[7] 450 Brookline Ave, Boston, MA 02215 USA
关键词
melanoma; immune checkpoint inhibition; ipilimumab; nivolumab; stable disease; PHASE-III; IPILIMUMAB; MELANOMA; DACARBAZINE; NIVOLUMAB;
D O I
10.1097/CJI.0000000000000470
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite the wide use of immune checkpoint inhibition for the treatment of melanoma, the mechanisms leading to long-term stable disease are incompletely understood. Patients with metastatic melanoma who had received ipilimumab alone or ipilimumab plus nivolumab 2+years prior and attained at least 6 months of stable disease were identified. Positron emission tomography/computed tomography (PET/CT) was performed. Pretreatment and posttreatment biopsies of areas of stable disease were assessed for tumor, fibrosis, and inflammation. Seven patients underwent PET/CT and tissue biopsy. Fluorodeoxyglucose avid lesions on PET/CT ranged from no activity to an SUV of 22. In 6 patients, the residual stable lesions were composed of necrosis and fibrosis with a prominent pigment containing macrophages and no residual melanoma. In 1 patient, a nodal lesion demonstrated melanoma with active inflammation. In most patients with durable stable disease after treatment with ipilimumab or ipilimumab/nivolumab, residual lesions demonstrated predominantly necrosis and fibrosis consistent with resolving lesions. The presence of melanophages in these samples may suggest ongoing immune surveillance. One patient did demonstrate residual melanoma, indicating the need for ongoing monitoring of this patient population.
引用
收藏
页码:192 / 196
页数:5
相关论文
共 50 条
  • [1] Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma
    Reddy, Swathi B.
    Possick, Jennifer D.
    Kluger, Harriet M.
    Galan, Anjela
    Han, Dale
    JOURNAL OF IMMUNOTHERAPY, 2017, 40 (08) : 307 - 311
  • [2] Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies
    Robert, Caroline
    Mateus, Christina
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2014, 198 (02): : 297 - 308
  • [3] CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients
    Goltz, Diane
    Gevensleben, Heidrun
    Vogt, Timo J.
    Dietrich, Joern
    Golletz, Carsten
    Bootz, Friedrich
    Kristiansen, Glen
    Landsberg, Jennifer
    Dietrich, Dimo
    JCI INSIGHT, 2018, 3 (13):
  • [4] Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy.
    Gide, Tuba Nur
    Quek, Camelia
    Madore, Jason
    Menzies, Alexander M.
    Dent, Rebecca
    Carlino, Matteo S.
    Guminski, Alex
    Saw, Robyn
    Thompson, John F.
    Wilmott, James S.
    Scolyer, Richard A.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [5] Anti-CTLA-4 therapy for malignant mesothelioma
    Guazzelli, Alice
    Bakker, Emyr
    Krstic-Demonacos, Marija
    Lisanti, Michael P.
    Sotgia, Federica
    Mutti, Luciano
    IMMUNOTHERAPY, 2017, 9 (03) : 273 - 280
  • [6] Immunologic impact of anti-CTLA-4 therapy
    Sharma, P.
    Tsavachidou, D.
    Kamat, A.
    Tang, D. Ng
    Chen, H.
    Fu, T.
    Troncoso, P.
    Wolchok, J.
    Logothetis, C. J.
    Allison, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
    Patel, Sandip P.
    Cano-Linson, Eleanor
    Chae, Young Kwang
    Schokrpur, Shiruyeh
    Lao, Christopher D.
    Powers, Benjamin C.
    Victor, Adrienne I.
    Onitilo, Adedayo A.
    Shin, Sarah
    Takebe, Naoko
    Threlkel, Sara
    Mcleod, Christine M.
    Chen, Helen X.
    Sharon, Elad
    Othus, Megan
    Ryan, Christopher W.
    Blanke, Charles D.
    Kurzrock, Razelle
    NPJ PRECISION ONCOLOGY, 2025, 9 (01)
  • [8] Clinical outcome and CD4+differentiation in anti-CTLA-4/radiation and anti-CTLA-4/steroid therapy.
    Dapodra, Anuj
    Da Silva, Ines Esteves Domingues Fires
    Lui, Kevin P.
    Pavlick, Anna C.
    Thong, Judy
    Osman, Iman
    Krogsgaard, Michelle
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
    Lipson, Evan J.
    Drake, Charles G.
    CLINICAL CANCER RESEARCH, 2011, 17 (22) : 6958 - 6962
  • [10] Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy
    Rogiers, Aljosja
    Dimitriou, Florentia
    Lobon, Irene
    Harvey, Catriona
    Vergara, Ismael A.
    da Silva, Ines Pires
    Lo, Serigne N.
    Scolyer, Richard A.
    Carlino, Matteo S.
    Menzies, Alexander M.
    Long, Georgina V.
    EUROPEAN JOURNAL OF CANCER, 2024, 198